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What is already known about this subject {#bcp13935-sec-0107}
========================================

Globally, around 16% of tuberculosis (TB) patients suffer from comorbid diabetes mellitusDiabetes is a risk factor for TB, altered pharmacokinetics and can thus impact pharmacological TB treatment outcomesIn recent years, multiple TB drug trials have been performed, yet a systematic overview of the inclusion of diabetes comorbidity and potential differential outcomes within these trials is lacking.

What this study adds {#bcp13935-sec-0108}
====================

This systematic review provides an overview of diabetes inclusion in recent TB drug trials performed around the worldOf the 41 studies included, \<1/3 TB drug trials reported the inclusion of patients with diabetesA total of 12 studies (29%) reported the inclusion of patients with diabetes, yet the vast majority of TB drug trials did not report the diagnostic criteria for diabetesNone of the studies reported differential outcomes for the TB--diabetes overlap subpopulation, warranting increased attention on the design and analyses of future TB drug trials

1. INTRODUCTION {#bcp13935-sec-0007}
===============

The dual burden of tuberculosis (TB) and diabetes mellitus (DM) is a major global public health problem.[1](#bcp13935-bib-0001){ref-type="ref"} In 2017, the World Health Organization reported 10 million cases of TB and 1.3 million TB‐related deaths.[2](#bcp13935-bib-0002){ref-type="ref"} Approximately 415 million people worldwide live with DM and another 318 million people have impaired glucose tolerance---a marker for future diabetes.[3](#bcp13935-bib-0003){ref-type="ref"} By 2040, these numbers are likely to grow to 642 million and 481 million, respectively.[4](#bcp13935-bib-0004){ref-type="ref"}

The global burden of TB‐DM overlap is high, with a prevalence of 16% globally, 17% in Asia, 7% in Africa, 24% in North America, 23% in Oceania, 11% in South America, and 6% in Europe.[1](#bcp13935-bib-0001){ref-type="ref"} The International Diabetes Federation (IDF) estimates that 46% of diabetes cases worldwide (around 175 million) are not diagnosed, with the highest proportions concentrated in Africa (62%) and southeast Asia (54%), coinciding with the greatest TB burden. Globally, 84% of all people with undiagnosed diabetes live in low‐income and middle‐income countries where the management of these people is rarely optimal.[5](#bcp13935-bib-0005){ref-type="ref"} DM could severely threaten TB control and may become most profound in resource‐poor areas where TB thrives.[6](#bcp13935-bib-0006){ref-type="ref"}

A systematic review and meta‐analysis of studies published between 1980--2010 reported that DM is associated with 69% higher risk of death and increased risk of TB relapse than TB patients without DM.[7](#bcp13935-bib-0007){ref-type="ref"} Since 2010, several large cohort studies reported unfavourable effects of DM on TB outcomes. DM was associated with more severe clinical manifestations of TB such as higher frequency of cavities on chest X‐ray and higher hospitalization rates.[8](#bcp13935-bib-0008){ref-type="ref"}, [9](#bcp13935-bib-0009){ref-type="ref"}, [10](#bcp13935-bib-0010){ref-type="ref"} Patients with DM were more likely to have up to 2 times higher TB reactivation, recurrence, and relapse.[8](#bcp13935-bib-0008){ref-type="ref"}, [9](#bcp13935-bib-0009){ref-type="ref"}, [10](#bcp13935-bib-0010){ref-type="ref"}, [11](#bcp13935-bib-0011){ref-type="ref"} TB‐DM patients were more likely to have delayed sputum conversion and higher probability of treatment failure.[8](#bcp13935-bib-0008){ref-type="ref"}, [9](#bcp13935-bib-0009){ref-type="ref"}, [12](#bcp13935-bib-0012){ref-type="ref"} A recent systematic review showed that glycaemic control has a favourable effect on TB treatment outcomes and, conversely, uncontrolled DM or poor glycaemic control (i.e. HbA1c \> 7%) was associated with delayed sputum conversion.[13](#bcp13935-bib-0013){ref-type="ref"}, [14](#bcp13935-bib-0014){ref-type="ref"}

Early screening for TB‐DM comorbidity can help clinicians to act promptly, thereby resulting in improved TB treatment outcomes.[15](#bcp13935-bib-0015){ref-type="ref"} Notably, given the profound impact of DM comorbidity on TB treatment outcomes and the call for intensified precision drug therapy, this comorbidity should receive higher priority in prospective randomized clinical TB drug efficacy trials. However, an overview of current data on TB‐DM comorbidity in recent TB drugs trials is lacking. This overview may help to raise awareness on the inclusion of DM comorbidity and could benefit the design of future TB drug trials. We therefore aimed to systematically review the inclusion of DM comorbidity in recent TB drug efficacy trials, with specific emphasis on differential outcomes of TB‐DM overlap patients.

2. METHODS {#bcp13935-sec-0008}
==========

2.1. Study design {#bcp13935-sec-0009}
-----------------

A systematic review was performed and reported according to the Preferred Reporting Items for Systematic review and Meta‐Analyses (PRISMA) statement ([Supporting information Appendix S1](#bcp13935-supitem-0001){ref-type="supplementary-material"}). The review was registered at PROSPERO (registration number: 71203) and is available online on <https://www.crd.york.ac.uk/prospero/display_record.php?> RecordID = 71203.

2.2. Information sources and search strategy {#bcp13935-sec-0010}
--------------------------------------------

In this review, the PubMed, Science Direct and [ClinicalTrials.gov](http://ClinicalTrials.gov) databases were systematically searched (in September 2017) for TB drug trials published between 1 January 2012 and 12 September 2017 using combinations of the keywords "tuberculosis", AND "drug" AND "trial". Full search criteria can be found in [Supporting information Appendix S2](#bcp13935-supitem-0002){ref-type="supplementary-material"}.

2.3. Inclusion criteria {#bcp13935-sec-0011}
-----------------------

The following eligibility criteria were applied for studies to be considered for inclusion: (i) published in peer‐reviewed journals; (ii) clinical trials or interventional studies of TB drug efficacy in TB confirmed (i.e. sputum smear or culture positive) patients that have been completed and published; and (iii) in English[16](#bcp13935-bib-0016){ref-type="ref"} and reflecting an original study. All criteria were required to be met for inclusion.

2.4. Exclusion criteria {#bcp13935-sec-0012}
-----------------------

Exclusion criteria were: (i) studies only assessing risk factors, biomarkers (and not drugs) in the TB trials; (ii) reviews, comments, conference abstracts, case reports or editorials; and (iii) study designs other than clinical trials.

2.5. Study selection {#bcp13935-sec-0013}
--------------------

Study screening based on title and abstract and selection based on full‐text assessment was first performed by one researcher (N.L.) and checked by a second researcher (M.Z.). Any discrepancies were solved by consensus and/or consultation of a third researcher if needed.

2.6. Data extraction and data items {#bcp13935-sec-0014}
-----------------------------------

Data extracted included the studies\' first author, the year of publication, study design, study sample size, number and percentage of comorbid DM patients, diagnostic criteria for DM, type of TB population, drug(s) studied, and country where the trial was performed. Again, data extraction was first performed by one researcher (N.L.) and subsequently checked by a second researcher (M.Z.). Any discrepancies were solved by consensus and/or consultation of a third researcher if needed.

2.7. Study measures and outcomes {#bcp13935-sec-0015}
--------------------------------

The primary outcome of interest was the percentage of TB drug trials performed around the world that included DM patients. Additionally, results were assessed per continent. Exploratory, more descriptive outcomes included differential outcomes of TB‐DM patients (if reported). Chi‐square tests were performed to assess potential statistical differences in inclusion (yes/no) of DM comorbidity across subgroups (e.g. type of TB and continent were trials were performed). A *P*‐value \<.05 was considered statistically significant.

2.8. Assessment of reporting bias {#bcp13935-sec-0016}
---------------------------------

To assess potential reporting bias, we searched for study protocols of each study to check recruitment criteria of DM patients in the eligible trials against reported population characteristics. If unclear, we contacted the study authors to get more information about the DM criteria and reported outcomes.

3. RESULTS {#bcp13935-sec-0017}
==========

3.1. Study selection {#bcp13935-sec-0018}
--------------------

After duplicates were removed, a total of 1177 records were screened based on abstract and title. We identified 54 potentially eligible full‐text papers of which 13 studies were excluded after detailed review (10 studies were noninterventional, and 3 assessed a diagnostic tool or the pharmacokinetics of TB drugs and not the efficacy of the TB drug itself). A flow diagram is presented in Figure [1](#bcp13935-fig-0001){ref-type="fig"} and study characteristics of the final selection of 41 trials are presented in Table [1](#bcp13935-tbl-0001){ref-type="table"}. Eligibility decisions for in‐ and excluded studies have been provided in [Supporting information Appendix S3](#bcp13935-supitem-0003){ref-type="supplementary-material"}. Of note, compared to our initial study protocol we did not apply the *full‐text being available* as an inclusion criterion, given that we did not restrict ourselves to online available full‐texts only but also contacted study authors to retrieve full‐texts.

![PRISMA flow diagram](BCP-85-1407-g001){#bcp13935-fig-0001}

###### 

Study characteristics of randomized clinical trials of anti‐tuberculosis (TB) drugs (n = 41)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author** ^**ref**^                                          **Year**   **Type of study**   **Sample size**   **DM patients (n, %)**                                                                                **Diagnostic criteria for DM**                                 **Type of TB**        **Drugs**                                                                                 **Country**
  ------------------------------------------------------------- ---------- ------------------- ----------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Diacon et al.[17](#bcp13935-bib-0017){ref-type="ref"}         2012       Phase 2 RCT         85                DM insulin dependent were excluded                                                                    Judge by the investigator                                      PTB                   Proteomanid, pyrazinamide, bedaquiline, rifafour, moxifloxacin                            South Africa

  Diacon et al.[18](#bcp13935-bib-0018){ref-type="ref"}         2012       Phase 2 RCT         89                DM insulin dependent were excluded                                                                    Judge by the investigator                                      PTB                   Proteomanid, rifafour                                                                     South Africa

  Lee et al.[19](#bcp13935-bib-0019){ref-type="ref"}            2012       Phase 2 RCT         39                14 (36%)                                                                                              Unexplained, medical history and blood examination performed   XDR PTB               Linezolid                                                                                 South Korea

  Gler et al.[20](#bcp13935-bib-0020){ref-type="ref"}           2012       Phase 2 RCT         481               Evidence of clinically significant metabolic, endocrine diseases were excluded                        unexplained                                                    MDR‐PTB               Delamanid                                                                                 Philippines, Peru, Latvia, Estonia, China, Japan, Korea, Egypt and USA

  Zhang et al.[21](#bcp13935-bib-0021){ref-type="ref"}          2013       Phase 2 RCT         38                5 (13.2%)                                                                                             Unexplained, blood biochemistry performed                      MDR‐TB                Delamanid                                                                                 China

  Jawahar et al.[22](#bcp13935-bib-0022){ref-type="ref"}        2013       Phase 3 RCT         416               Excluded                                                                                                                                                             PTB                   Moxifloxacin, gatifloxacin                                                                India

  Wang et al.[23](#bcp13935-bib-0023){ref-type="ref"}           2013       Phase 2 RCT                           100%                                                                                                  Fasting blood glucose and oral glucose tolerance test          PTB                   Retinol, vitamin D                                                                        China

  Jindani et al.[24](#bcp13935-bib-0024){ref-type="ref"}        2014       Phase 3 RCT 3       827               Unclear                                                                                                                                                              PTB                   Rifapentine, moxifloxacin                                                                 Zimbabwe, Botswana, Zambia, South Africa

  Diacon et al.[25](#bcp13935-bib-0025){ref-type="ref"}         2014       Phase 2 RCT         160               Unclear                                                                                                                                                              MDR‐PTB               Bedaquiline                                                                               Brazil, India, Philippines, Latvia, Peru, South Africa, Thailand

  Gillespie et al.[26](#bcp13935-bib-0026){ref-type="ref"}      2014       Phase 3 RCT         1931              Excluded                                                                                              Unexplained                                                    PTB                   Moxifloxacin                                                                              South Africa, India, Tanzania, Kenya Thailand, Malaysia, Zambia, China, Mexico

  Nunn et al.[27](#bcp13935-bib-0027){ref-type="ref"}           2014       Phase 3 RCT         1348              Unclear                                                                                                                                                              PTB                   Isoniazid, rifampicin, pyrazinamide, ethambutol, prothionamide                            Africa, Asia, Latin America

  Luangchosiri et al.[28](#bcp13935-bib-0028){ref-type="ref"}   2015       Phase 4 RCT         55                Unclear                                                                                                                                                              PTB                   Silymarin                                                                                 Thailand

  Diacon et al.[29](#bcp13935-bib-0029){ref-type="ref"}         2015       Phase 2 RCT         105               DM insulin dependent were excluded                                                                    Unexplained                                                    PTB                   Bedaquiline, proteomanid, pyrazinamide, clofazimine, rifafour                             South Africa

  Daley et al.[30](#bcp13935-bib-0030){ref-type="ref"}          2015       Phase 3 RCT         247               Unclear                                                                                                                                                              PTB                   Vitamin D                                                                                 India

  Dawson et al.[31](#bcp13935-bib-0031){ref-type="ref"}         2015       Phase 2 RCT         207               Excluded                                                                                              History of DM                                                  PTB                   Moxifloxacin, proteomanid, pyraziamide                                                    South Africa, Tanzania

  Dorman et al.[32](#bcp13935-bib-0032){ref-type="ref"}         2015       Phase 2 RCT         334               Unclear                                                                                                                                                              PTB                   Rifapentine                                                                               USA, Brazil, Uganda, Canada, South Africa, Spain

  Heinrich et al.[33](#bcp13935-bib-0033){ref-type="ref"}       2015       Phase 2 RCT         90                DM insulin dependent were excluded                                                                    Random blood glucose                                           PTB                   SQ109, rifampicin                                                                         South Africa

  Merle et al.[34](#bcp13935-bib-0034){ref-type="ref"}          2015       Phase 3 RCT         1836              Excluded                                                                                                                                                             PTB                   Gatifloxacin                                                                              Benin, Guinea, Kenya, Senegal and South Africa

  Mily et al.[35](#bcp13935-bib-0035){ref-type="ref"}           2015       Phase 2 RCT         288               Excluded                                                                                              History of DM                                                  PTB                   Vitamin D3                                                                                Bangladesh

  Dawson et al.[31](#bcp13935-bib-0031){ref-type="ref"}         2015       Phase 2 RCT         153               Evidence of clinically significant metabolic endocrine diseases, DM insulin dependent were excluded   Random blood glucose                                           PTB                   Rifapentine                                                                               Tanzania, South Africa

  Wu et al.[36](#bcp13935-bib-0036){ref-type="ref"}             2015       Phase 4 RCT         161               24 (14.9%)                                                                                            Random blood glucose                                           PTB                   Isoniazid, rifampicin, pyrazinamide, ethambuthol (FDC compared to separate formulation)   Taiwan

  Tang et al.[37](#bcp13935-bib-0037){ref-type="ref"}           2015       Phase 4 RCT         65                13 (20%)                                                                                              Random blood glucose                                           XDR‐TB                Linezolid                                                                                 China

  Tang et al.[38](#bcp13935-bib-0038){ref-type="ref"}           2015       Phase 4 RCT         105               21 (20%)                                                                                              History of DM                                                  MDR PTB               Clofazimin                                                                                China

  Tukvadze et al.[39](#bcp13935-bib-0039){ref-type="ref"}       2015       Phase 2 RCT         199               10 (5%)                                                                                               History of DM                                                  PTB                   Vitamin D                                                                                 Georgia

  Aseffa et al.[40](#bcp13935-bib-0040){ref-type="ref"}         2016       Phase 4 RCT         1000              Excluded                                                                                              Fasting blood glucose                                          PTB                   Isoniazid, rifampicin, pyrazinamide, ethambuthol: FDC *vs* loose regimen                  Ethiopia, Nigeria

  Conde et al.[41](#bcp13935-bib-0041){ref-type="ref"}          2016       Phase 2 RCT         121               HbA1c \>8 g/dl were excluded                                                                          HbA1c                                                          PTB                   Rifapentine, moixifloxacin, pyrazinamide, isoniazid                                       Brazil

  Furin et al.[42](#bcp13935-bib-0042){ref-type="ref"}          2016       Phase 2 RCT         75                Excluded                                                                                              Random blood glucose                                           PTB                   Azd5847                                                                                   South Africa

  Heemskerk et al.[43](#bcp13935-bib-0043){ref-type="ref"}      2016       Phase 4 RCT         817               Unclear                                                                                                                                                              Meningitis TB         Rifampicin, levofloxacin, isoniazid, pyrazinamide, ethambutol, streptomycin               Vietnam

  Kang et al.[44](#bcp13935-bib-0044){ref-type="ref"}           2016       Phase 3 RCT         151               5 (3.3%)                                                                                              Unexplained                                                    MDR‐TB                Levofloxacin, moxifloxacin                                                                South Korea

  Milstein et al.[45](#bcp13935-bib-0045){ref-type="ref"}       2016       Phase 2 RCT         180               Uncontrolled DM HbA1c \>7.5 excluded                                                                  HbA1c                                                          PTB                   Higher dose rifampin                                                                      Peru, USA, UK

  Pym et al.[46](#bcp13935-bib-0046){ref-type="ref"}            2016       Phase 2 RCT         233               Unclear                                                                                                                                                              MDR‐PTB and XDR‐PTB   Bedaquiline                                                                               China, Estonia, Kenya, Korea, Latvia, Peru, Philippines, Russia, South Africa, Thailand, Turkey, Ukraine

  Chesdachai et al.[47](#bcp13935-bib-0047){ref-type="ref"}     2016       Phase 2 RCT         31                3 (9.7%)                                                                                              History of DM                                                  PTB                   Vitamin D3                                                                                Georgia

  Zhang et al.[48](#bcp13935-bib-0048){ref-type="ref"}          2016       Phase 4 RCT         370               34 (9.2%)                                                                                             Unexplained                                                    Unspecified           Silybum marianum capsule as hepatoprotectant                                              China

  Aarnoutse et al.[49](#bcp13935-bib-0049){ref-type="ref"}      2017       Phase 2 RCT         150               Excluded                                                                                              Medical History                                                PTB                   Rifampicin                                                                                Tanzania

  Alsultan et al.[50](#bcp13935-bib-0050){ref-type="ref"}       2017       Phase 2 RCT         60                Excluded                                                                                              Random blood glucose \> 150 mg/dL excluded                     PTB                   AZD‐5847\                                                                                 South Africa
                                                                                                                                                                                                                                                                                                            Rifafour                                                                                  

  Boeree et al.[51](#bcp13935-bib-0051){ref-type="ref"}         2017       Phase 2 RCT         365               Uncontrolled or DM insulin dependent were excluded                                                    History of DM                                                  PTB                   Rifampicin, moxifloxacin, SQ109                                                           Tanzania, South Africa

  Boutoun et al.[52](#bcp13935-bib-0052){ref-type="ref"}        2017       Phase 2 RCT         111               Poorly controlled DM (HbA1c \>9%) were excluded                                                       HbA1c                                                          MDR‐PTB               Levofloxacin                                                                              Peru, South Africa

  Batbold et al.[53](#bcp13935-bib-0053){ref-type="ref"}        2017       Phase 3 RCT         269               2 (0.7%)                                                                                              Random blood glucose                                           PTB                   Imunoxel honey lozenges                                                                   Mongolia, Ukraine

  Lee et al.[54](#bcp13935-bib-0054){ref-type="ref"}            2017       Phase 2 RCT         429               Unclear                                                                                                                                                              PTB                   Linezolid, ethambutol                                                                     South Korea

  Sigal et al.[55](#bcp13935-bib-0055){ref-type="ref"}          2017       Phase 2 RCT         389               Unclear                                                                                                                                                              PTB                   Rifapentine, isoniazid, pyrazinamide, ethambutol                                          USA

  Ganmaa et al.[56](#bcp13935-bib-0056){ref-type="ref"}         2017       Phase 4 RCT         380               19 (5%)                                                                                               Unexplained                                                    PTB                   Vitamin D3                                                                                Mongolia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DM: diabetes mellitus; RCT: randomised controlled trial; PTB: pulmonary tuberculosis; MDR: multidrug resistant; XDR: extensively drug resistant, FDC: fixed drug combination.

3.2. Study characteristics {#bcp13935-sec-0019}
--------------------------

The vast majority of TB drug trials was exclusively performed in Asia (*n =* 15; 37%) and Africa (*n =* 13; 32%). North America (USA) and South America (Brazil) contributed only one trial each, while others were performed in Europe (*n =* 2, both in Georgia) or in multiple sites around the world (*n =* 9). Study size varied between 31 patients for a TB trial performed in Georgia[25](#bcp13935-bib-0025){ref-type="ref"} and 1931 for a multicentre trial with moxifloxacin.[47](#bcp13935-bib-0047){ref-type="ref"} Drugs mostly studied were isoniazid, [rifampicin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765), [pyrazinamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7287) and ethambutol.

3.3. Overview of DM comorbidity in TB drug trials {#bcp13935-sec-0020}
-------------------------------------------------

Out of the included 41 trials, 12 (29.3%) reported DM comorbidity among the study participants (Figure [2](#bcp13935-fig-0002){ref-type="fig"}).

![Inclusion status of diabetes mellitus (DM) in tuberculosis drug trials 2012--2017 (total n = 41)](BCP-85-1407-g002){#bcp13935-fig-0002}

Nine trials (21.9%) clearly excluded patients with any DM comorbidity, 10 (24.4%) excluded only [insulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012)‐dependent or uncontrolled DM but did not report data of noninsulin dependent DM patients, and 10 (24.3%) did not mention whether DM was included or excluded. DM was included in 9 of the 15 (60%) trials performed in Asia and in both European trials (Figure [2](#bcp13935-fig-0002){ref-type="fig"}). In 12 of the 13 (92.3%) African TB trials, patients with DM comorbidity were excluded. There was a significant difference (*P* = .006) between DM inclusion in Asian and African TB drug trials. Of the 12 trials that included patients with DM comorbidity regardless of severity, 5 studies did not report the diagnostic criteria for DM. Three studies used random blood glucose.[36](#bcp13935-bib-0036){ref-type="ref"}, [37](#bcp13935-bib-0037){ref-type="ref"}, [54](#bcp13935-bib-0054){ref-type="ref"} One study used fasting plasma glucose and 2‐hour oral glucose tolerance test[23](#bcp13935-bib-0023){ref-type="ref"} and 3 studies obtained DM comorbidity from patients\' history.[38](#bcp13935-bib-0038){ref-type="ref"}, [39](#bcp13935-bib-0039){ref-type="ref"}, [48](#bcp13935-bib-0048){ref-type="ref"} The prevalence of DM among TB patients in the 12 trials ranged from 0.7% in Mongolia and Ukraine[54](#bcp13935-bib-0054){ref-type="ref"} to 36% in South Korea[19](#bcp13935-bib-0019){ref-type="ref"} with overall median DM prevalence of 12.3%. Naturally, in the study that specifically focused on TB‐DM overlap, this was 100%.[23](#bcp13935-bib-0023){ref-type="ref"} Three out of 12 trials reporting DM comorbidity showed that DM was the most common comorbidity.[37](#bcp13935-bib-0037){ref-type="ref"}, [38](#bcp13935-bib-0038){ref-type="ref"}, [39](#bcp13935-bib-0039){ref-type="ref"} Of the 12 trials reporting DM comorbidity, none of the studies assessed any potential effects of DM on anti‐TB drugs outcomes. Of note, 6 out of 9 (67%) drug trials for drug‐resistant TB included DM comorbidity in their baseline characteristics, while only 4 out of the 32 (12.5%) drug‐susceptible TB trials included DM comorbidity in their baseline characteristics, and this differed significantly (*P* = .003).

4. DISCUSSION {#bcp13935-sec-0021}
=============

Data from this systematic review indicate that \<1/3 recent TB drug efficacy trials reported the inclusion of patients with DM comorbidity regardless of DM severity. If included, diagnostic criteria for DM were often unclear. Notably, inclusion of DM was relatively higher in MDR‐TB drug trials and trials performed in Asia. Although DM patients were included in some studies, no differential outcomes for DM‐TB overlap patients were reported.

Asia has high DM prevalence among TB patients; therefore, it is not surprising that most trials that included DM comorbidity were conducted in Asia, mainly China. China and India are 2 leading countries that have piloted the TB‐DM collaborative framework and have demonstrated bidirectional screening for both diseases.[57](#bcp13935-bib-0057){ref-type="ref"}, [58](#bcp13935-bib-0058){ref-type="ref"}, [59](#bcp13935-bib-0059){ref-type="ref"} Although India is one of the pilot countries, most drug trials conducted in India had unclear criteria for DM comorbidity, and one Indian trial even excluded DM patients. Most trials that excluded DM comorbidity were conducted in Africa. Notably, South Africa has high prevalence of TB, and TB ranks third in diseases that causes life‐years lost,[60](#bcp13935-bib-0060){ref-type="ref"} but none of the TB drug trials conducted in South Africa screened for DM comorbidity. For South Africa, this omission may be related to the relatively low comorbid DM rates compared with, for example, comorbid human immunodeficiency virus/acquired immune deficiency syndrome. However, the few TB drug trials conducted in America also did not assess DM comorbidity, while DM rates in these continents are relatively high.[1](#bcp13935-bib-0001){ref-type="ref"} In particular, multidrug‐resistant TB (MDR‐TB) continues to be a public health crisis and in MDR‐TB the importance of DM comorbidity seems more widely acknowledged. Indeed, in a meta‐analysis it was shown that DM was an independent risk factor for MDR‐TB and, in most drug‐resistant TB trials, DM comorbidity was more often included.[61](#bcp13935-bib-0061){ref-type="ref"} Regarding the effect of DM comorbidity to unfavourable treatment of TB, none of the TB trials that included DM comorbidity reported specific outcomes related to the TB‐DM subpopulation. A systematic review suggested a phase III clinical trial to ensure the safe use of new TB drugs in diabetes patients.[62](#bcp13935-bib-0062){ref-type="ref"} Indeed, there is still a lack of sufficient data regarding pharmacokinetic and clinical data of TB drugs in DM patients, despite the continuous growth of DM patients in the future that will cause a further threat to TB control.

Some TB drug trials excluded insulin‐dependent DM patients. Insulin‐dependent diabetes will usually reflect uncontrolled DM.[63](#bcp13935-bib-0063){ref-type="ref"} As TB patients with uncontrolled DM are more likely to fail on treatment, trials that are specifically designed to show efficacy of a new TB drug usually exclude those patients as they could compromise trial results.[64](#bcp13935-bib-0064){ref-type="ref"}

Several underlying mechanisms to understand adverse treatment outcomes of TB due to hyperglycaemia have been suggested.[65](#bcp13935-bib-0065){ref-type="ref"}, [66](#bcp13935-bib-0066){ref-type="ref"} One mechanism is related to an altered immunological response[67](#bcp13935-bib-0067){ref-type="ref"}, [68](#bcp13935-bib-0068){ref-type="ref"}, [69](#bcp13935-bib-0069){ref-type="ref"} which is important, but difficult to account for in TB treatment decisions. Another factor that explains unfavourable treatment outcomes are the drug--drug and drug--disease interactions. A systematic review that assessed the pharmacokinetics of first‐line TB drugs showed that age, sex, malnutrition, food intake, genetic factors and comorbidities (mainly human immunodeficiency virus and diabetes) could all play a role.[70](#bcp13935-bib-0070){ref-type="ref"}

Altered pharmacokinetics of anti‐TB drugs may warrant a need for routine monitoring and modification of the regimens in patients with DM. American Thoracic Society, Center for Disease Control and Prevention, and Infectious Diseases Society of America guidelines suggest early identification of patients at increased risk of relapse such as those with DM[71](#bcp13935-bib-0071){ref-type="ref"} as well as therapeutic drug monitoring (TDM). TDM does allow for timely, informed decisions regarding the need for dose adjustment when necessary. TDM is considered to be helpful in situations in which clinicians are confronted with drug malabsorption, drug under‐dosing, or clinically important drug--drug or drug--disease interactions, such as diabetes comorbidity.[72](#bcp13935-bib-0072){ref-type="ref"}

To our knowledge, this is the first systematic review specifically focusing on the inclusion of DM in TB drug trials. Major strengths are the search within 3 different databases, double checking of inclusion and data extraction and reporting according to the standardized PRISMA statement. Also, some limitations need to be mentioned. First, given the focus on English language manuscripts and our own restricted language knowledge, we had to exclude the few trials that were only published in a local language. These trials could potentially be informative but may often be less generalizable as the larger multicountry trials. Second, the studies included in this review used different diagnostic criteria for DM that could induce the risk of over‐ or under representation of DM patients among studies. Also, we should consider that if studies did not explicitly listed DM as an exclusion criterion, it may well be that DM patients were eligible but were not included in the trial. Third, no meta‐analysis was performed because we felt that simply combining all rates would be less informative than providing separate DM inclusion rates by region/continent. Fourth, in the PubMed search, we applied a *full‐text available filter* (see [Supporting information Appendix S2](#bcp13935-supitem-0002){ref-type="supplementary-material"}). This could have excluded some full manuscripts that only had an abstract available in PubMed. Retrospectively, we have checked the impact of this filter. In the search without the filter, 21 additional hits (equalling 3.7% more hits) were found, although, after inspection, none were eligible. Finally, we could not assess reporting bias as clinical trials around the world can be registered in many different databases and we received little response from contacting the study authors. Therefore, comparing published trials with registered trials was not feasible.

Regarding future research and policies, it is important for TB drug trials to screen for DM comorbidity, aim for a representative, real‐life, DM percentage according to the location and appropriately diagnose DM. Alternatively, a separate multicentre trial in diabetic patients could be considered where also more emphasis can be placed on diabetes‐specific outcomes such as hypoglycaemias. Intensified research and development of TB drugs, particularly in the context of comorbidities such as DM, play a crucial role to improve TB control and contribute to reductions in TB incidence and mortality required to reach global TB targets by 2035, one of the pillars of World Health Organization\'s Post‐2015 Global TB Strategy.[16](#bcp13935-bib-0016){ref-type="ref"}

Including DM comorbidity in TB drug trials will allow for the study of possible DM‐TB drug--drug and drug--disease interactions that can alter the pharmacokinetics, safety and clinical effects of the TB drugs. Eventually, these findings will enable us to assess TB‐DM patients\' individual need for personalize treatment options and lead to better real‐world TB‐DM outcomes and possibly lower resistance rates.

5. CONCLUSION {#bcp13935-sec-0022}
=============

To conclude, current inclusion of DM comorbidity in recent TB drug efficacy trials is suboptimal compared with its increasing prevalence and significance. Considering the considerable prevalence and impact of DM comorbidity, the inclusion of patients with DM in future TB efficacy drug trials warrants increased attention and requires a joint effort of trialists, clinicians and policy makers alike.

5.1. Nomenclature of targets and ligands {#bcp13935-sec-0023}
----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY.[73](#bcp13935-bib-0073){ref-type="ref"}
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